FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial

Alternative Medicine
AstraZenecaClinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed across the world with regulators in the US, UK, Brazil, South Africa and Japan confirming that it was safe to do so.

The Food and Drug Administration (FDA) authorised the restart in the US, following the resumption of trials in other countries in recent weeks. The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial.

Leave a Reply

Your email address will not be published. Required fields are marked *